So should Immunic (NASDAQ:IMUX) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company ...

Immunic (IMUX – Research Report) received a Buy rating and a $1.20 price target from William Blair analyst Matt Phipps yesterday. The company’s ...

NEW YORK, April 10, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule ...

NASDAQ:IMUX opened at $0.90 on Thursday. The firm has a 50-day moving average of $1.08 and a two-hundred day moving average of $1.16. The stock has a market cap of $81.15 million, a P/E ratio of ...

Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and ...

Fintel reports that on March 25, 2025, William Blair initiated coverage of Immunic (NasdaqGS:IMUX) with a Outperform recommendation. Analyst Price Forecast Suggests 965.88% Upside As of March 19 ...

Immunic ( ($IMUX) ) has shared an announcement. On April 9, 2025, Immunic, Inc. announced a securities purchase agreement with institutional and ...

Shares of IMUX stock opened at $1.07 on Tuesday. The firm has a market cap of $95.93 million, a price-to-earnings ratio of -0.87 and a beta of 1.89. Immunic has a 12 month low of $0.92 and a 12 ...

NEW YORK, April 9, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule ...